Sponsored equine feature spotlights vitamin E and neurologic risk: full analysis
A new sponsored educational article from The Horse is drawing attention to a familiar but clinically important issue in equine practice: vitamin E’s role in protecting horses from neuromuscular disease. The April 23, 2026 piece, sponsored by Kentucky Performance Products, features Carrie Finno, DVM, PhD, Dipl. ACVIM, a UC Davis veterinary clinician-scientist whose research focuses on vitamin E and neurodegeneration in horses. It’s not a new study or regulatory action, but it does elevate a topic with direct relevance for equine veterinarians managing neurologic and muscle cases. (thehorse.com)
The background here is longstanding. Veterinary literature has tied vitamin E deficiency to several equine neurologic disorders for years, most notably equine motor neuron disease, an acquired neurodegenerative disorder in adult horses, and equine neuroaxonal dystrophy/equine degenerative myeloencephalopathy, which tends to affect young horses with genetic susceptibility. A 2012 review in the Journal of Veterinary Internal Medicine described vitamin E as essential for normal neuromuscular function, while more recent AAEP proceedings continue to frame NAD/EDM as an inherited neurodegenerative disease associated with vitamin E deficiency in the first year of life. (academic.oup.com)
That context matters because the Horse article lands in an environment where many horses still face nutritional risk factors. Fresh grass is the primary natural source of vitamin E, and forage vitamin E content can fall with drought, harvesting, baling, storage, and other management variables. Merck’s veterinary guidance says EMND is invariably associated with vitamin E deficiency, and notes that EDM is often associated with deficiency as well. In practice, that means horses with limited pasture access, heavy reliance on stored hay, or suspected malabsorption can present a nutritional history that deserves more attention during neurologic evaluation. (merckvetmanual.com)
The clinical details are nuanced. EMND and NAD/EDM are not interchangeable, and neither should be confused with more common rule-outs such as cervical vertebral compressive myelopathy or equine protozoal myeloencephalitis. AAEP proceedings note that NAD/EDM is one of the most common causes of spinal ataxia in horses and can present with subtle, gradually progressive signs in young animals. The same source emphasizes that other spinal cord diseases must be ruled out, while the 2012 review notes that vitamin E supplementation is used empirically in some neurologic conditions for possible neuroprotective benefit, even when the disease is not caused by vitamin E deficiency itself. (aaep.org)
Expert perspective is built into the Horse piece through Finno’s involvement. The article identifies her as a veterinary clinician-scientist at UC Davis with more than 120 papers and research centered on the interplay of vitamin E and neurodegeneration. Broader expert guidance aligns with that emphasis. Merck recommends highly bioavailable natural vitamin E for horses diagnosed with EMND, and AAEP proceedings note preventive supplementation strategies for at-risk mares and foals from families with known NAD/EDM history. (thehorse.com)
Why it matters: For veterinary professionals, this is a reminder that nutrition remains part of neurology, not a separate conversation. Serum vitamin E assessment, forage history, pasture access, age, breed background, and family history can all help sharpen differentials when horses present with weakness, ataxia, muscle wasting, or poor performance. It also matters for client communication: pet parents may view vitamin E as a general wellness supplement, while clinicians need to frame it as a targeted part of prevention, workup, or supportive management, depending on the case. Sponsored coverage can raise awareness, but veterinarians still have to separate education from evidence strength and tailor recommendations to diagnosis, formulation, and bioavailability. (merckvetmanual.com)
What to watch: The next step isn’t likely to be a single breakthrough announcement, but continued refinement in earlier detection, biomarker use, risk-based supplementation, and clearer guidance on when vitamin E is preventive, supportive, or unlikely to change outcome once neurologic damage is established. (merckvetmanual.com)